Neuropeptides
Volume 44, Issue 5 , Pages 373-383 , October 2010

The vasoactive intestinal peptide-receptor system is involved in human glioblastoma cell migration

Received 16 December 2009 ,Accepted 12 June 2010.

References 

  1. Allalunis-Turner MJ, Barron GM, Day RS, Dobler KD, Mirzayans R. Isolation of two cell lines from a human malignant glioma specimen differing in sensitivity to radiation and chemotherapeutic drugs. Radiat. Res. 1993;134:349–354
  2. Alleaume C, Eychene A, Harnois T, Bourmeyster N, Constantin B, Caigneaux E, et al. Vasoactive intestinal peptide-induced neurite remodeling in human neuroblastoma SH-SY5Y cells implicates the Cdc42 GTPase and is independent of Ras-ERK pathway. Exp. Cell Res. 2004;299:511–524
  3. Brenneman DE, Gozes I. A femtomolar-acting neuroprotective peptide. J. Clin. Invest. 1996;97:2299–2307
  4. Cameron DB, Galas L, Jiang Y, Raoult E, Vaudry D, Komuro H. Cerebellar cortical-layer-specific control of neuronal migration by pituitary adenylate cyclase-activating polypeptide. Neuroscience. 2007;146:697–712
  5. Demuth T, Berens ME. Molecular mechanisms of glioma cell migration and invasion. J. Neurooncol. 2004;70:217–228
  6. Dufes C, Alleaume C, Montoni A, Olivier JC, Muller JM. Effects of the vasoactive intestinal peptide (VIP) and related peptides on glioblastoma cell growth in vitro. J. Mol. Neurosci. 2003;21:91–102
  7. Fabry M, Cabrele C, Hocker H, Beck-Sickinger AG. Differently labeled peptide ligands for rapid investigation of receptor expression on a new human glioblastoma cell line. Peptides. 2000;21:1885–1893
  8. Fernández-Martínez AB, Bajo AM, Sánchez-Chapado M, Prieto JC, Carmena MJ. Vasoactive intestinal peptide behaves as a pro-metastatic factor in human prostate cancer cells. Prostate. 2009;69:774–786
  9. Gozes I, Brenneman DE. A new concept in the pharmacology of neuroprotection. J. Mol. Neurosci. 2000;14:61–68
  10. Gozes I, McCune SK, Jacobson L, Warren D, Moody TW, Fridkin M, et al. An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system. J. Pharmacol. Exp. Ther. 1991;257:959–966
  11. Guan CX, Zhang M, Qin XQ, Cui YR, Luo ZQ, Bai HB, et al. Vasoactive intestinal peptide enhances wound healing and proliferation of human bronchial epithelial cells. Peptides. 2006;27:3107–3114
  12. Heraud C, Hilairet S, Muller JM, Leterrier JF, Chadeneau C. Neuritogenesis induced by vasoactive intestinal peptide, pituitary adenylate cyclase-activating polypeptide, and peptide histidine methionine in SH-SY5y cells is associated with regulated expression of cytoskeleton mRNAs and proteins. J. Neurosci. Res. 2004;75:320–329
  13. Holland EC. Glioblastoma multiforme: the terminator. Proc. Natl. Acad. Sci. USA. 2000;97:6242–6244
  14. Jaggi M, Prasad S, Singh AT, Praveen R, Dutt S, Mathur A, et al. Anticancer activity of a peptide combination in gastrointestinal cancers targeting multiple neuropeptide receptors. Invest New Drugs. 2008;26:489–504
  15. Laburthe M, Couvineau A, Tan V. Class II G protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology. Peptides. 2007;28:1631–1639
  16. Ladwein, M., Rottner, K., 2008. On the Rho’d: the regulation of membrane protrusions by Rho-GTPases. In: FEBS Lett. pp. 2066–2074.
  17. Lara-Marquez M, O’Dorisio M, O’Dorisio T, Shah M, Karacay B. Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells. J. Immunol. 2001;166:2522–2530
  18. Lutz EM, Ronaldson E, Shaw P, Johnson MS, Holland PJ, Mitchell R. Characterization of novel splice variants of the PAC1 receptor in human neuroblastoma cells: consequences for signaling by VIP and PACAP. Mol. Cell Neurosci. 2006;31:193–209
  19. Martin JL, Rose K, Hughes GJ, Magistretti PJ. [mono[125I]iodo-Tyr10, MetO17]-Vasoactive intestinal polypeptide. Preparation, characterization, and use for radioimmunoassay and receptor binding. J. Biol. Chem. 1986;261:5320–5327
  20. Masmoudi-Kouki O, Gandolfo P, Castel H, Leprince J, Fournier A, Dejda A, et al. Role of PACAP and VIP in astroglial functions. Peptides. 2007;28:1753–1760
  21. Mayer C, Popanda O, Zelezny O, von Brevern MC, Bach A, Bartsch H, et al. DNA repair capacity after gamma-irradiation and expression profiles of DNA repair genes in resting and proliferating human peripheral blood lymphocytes. DNA Repair (Amst.). 2002;1:237–250
  22. Mehler MF. Mechanisms regulating lineage diversity during mammalian cerebral cortical neurogenesis and gliogenesis. Results Probl. Cell Differ. 2002;39:27–52
  23. Moody TW, Leyton J, Chan D, Brenneman DC, Fridkin M, Gelber E, et al. VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells. Breast Cancer Res. Treat. 2001;68:55–64
  24. Moody TW, Zia F, Draoui M, Brenneman DE, Fridkin M, Davidson A, et al. A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth. Proc. Natl. Acad. Sci. 1993;90:4345–4349
  25. Muller JM, Debaigt C, Goursaud S, Montoni A, Pineau N, Meunier AC, et al. Unconventional binding sites and receptors for VIP and related peptides PACAP and PHI/PHM: an update. Peptides. 2007;28:1655–1666
  26. Muller JM, Lelievre V, Becq-Giraudon L, Meunier AC. VIP as a cell-growth and differentiation neuromodulator role in neurodevelopment. Mol. Neurobiol. 1995;10:115–134
  27. Muller JM, Philippe M, Chevrier L, Heraud C, Alleaume C, Chadeneau C. The VIP-receptor system in neuroblastoma cells. Regul. Pept. 2006;137:34–41
  28. Nagakawa O, Murata J, Junicho A, Matsuda T, Fujiuchi Y, Fuse H, et al. Vasoactive intestinal peptide (VIP) enhances the cell motility of androgen receptor-transfected DU-145 prostate cancer cells (DU-145/AR). Cancer Lett. 2002;176:93–99
  29. Ogasawara M, Murata J, Ayukawa K, Saimi I. Differential effect of intestinal neuropeptides on invasion and migration of colon carcinoma cells in vitro. Cancer Lett. 1997;116:111–116
  30. Ogasawara M, Murata J, Kamitani Y, Hayashi K, Saiki I. Inhibition by vasoactive intestinal polypeptide (VIP) of angiogenesis induced by murine Colon 26-L5 carcinoma cells metastasized in liver. Clin. Exp. Metastasis. 1999;17:283–291
  31. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J. Neuropathol. Exp. Neurol. 2005;64:479–489
  32. Pence JC, Shorter NA. The autocrine function of vasoactive intestinal peptide on human neuroblastoma cell growth and differentiation. Arch. Surg. 1993;128:591–595
  33. Quigley, M.R., Post, C., Ehrlich, G., 2007. Some speculation on the origin of glioblastoma. Neurosurg. Rev. 30, 16–20 (discussion 20-11).
  34. Reubi JC. In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging. J. Nucl. Med. 1995;36:1846–1853
  35. Robberecht P, Woussen-Colle MC, Vertongen P, De Neef P, Hou X, Salmon I, et al. Expression of pituitary adenylate cyclase activating polypeptide (PACAP) receptors in human glial cell tumors. Peptides. 1994;15:661–665
  36. Sakai Y, Hashimoto H, Shintani N, Katoh H, Negishi M, Kawaguchi C, et al. PACAP activates Rac1 and synergizes with NGF to activate ERK1/2, thereby inducing neurite outgrowth in PC12 cells. Brain Res. Mol. Brain Res. 2004;123:18–26
  37. Sharma A, Walters J, Gozes Y, Fridkin M, Brenneman D, Gozes I, et al. A vasoactive intestinal peptide antagonist inhibits the growth of glioblastoma cells. J. Mol. Neurosci. 2001;17:331–339
  38. Vertongen P, Camby I, Darro F, Kiss R, Robberecht P. VIP and pituitary adenylate cyclase activating polypeptide (PACAP) have an antiproliferative effect on the T98G human glioblastoma cell line through interaction with VIP2 receptor. Neuropeptides. 1996;30:491–496
  39. Vescovi AL, Galli R, Reynolds BA. Brain tumour stem cells. Nat. Rev. Cancer. 2006;6:425–436
  40. Yamazaki D, Kurisu S, Takenawa T. Regulation of cancer cell motility through actin reorganization. Cancer Sci. 2005;96:379–386
  41. Zupan V, Hill JM, Brenneman DE, Gozes I, Fridkin M, Robberecht P, et al. Involvement of pituitary adenylate cyclase-activating polypeptide II vasoactive intestinal peptide 2 receptor in mouse neocortical astrocytogenesis. J. Neurochem. 1998;70:2165–2173

PII: S0143-4179(10)00067-3

doi: 10.1016/j.npep.2010.06.003

Neuropeptides
Volume 44, Issue 5 , Pages 373-383 , October 2010

Article Tools

* Image Usage & Resolution